Eversense trial expands to pediatric diabetes patients
By HME News Staff
Updated 10:41 AM CDT, Wed April 19, 2023
GERMANTOWN, Md. – The first pediatric patient in the ENHANCE clinical trial has been inserted with the Eversense 365-day system, said Senseonics Holdings, a medical technology company focused on the development of long-term implantable CGMs. “It’s a priority for Senseonics to extend the benefits of Eversense to the pediatric patient population,” said Francine Kaufman, MD, chief medical officer for Senseonics. “The differentiated features of our long-term implantable Eversense are uniquely suited to benefit pediatrics and enable parents and their children to work together to manage diabetes.” The ENHANCE trial will evaluate the accuracy and safety of the Eversense for up to one year. More than 165 adults received the Eversense in trials and the last patient is expected to submit their data during the third quarter of 2023. An investigational device exemption supplement was submitted and approved for expansion of the trial to allow for patients ages 14 to 18.
- Read about Ascensia’s “big leap forward” with the Eversense 3.
Comments